MADISON, Wis.--(BUSINESS WIRE)--A new microsatellite instability (MSI) system launched today by Promega Corporation enables cancer researchers to evaluate a new set of unique MSI markers that may ...
Paris, March 12, 2025 – MSInsight, an innovative start-up specializing in precision medicine in oncology, announces the successful completion of its €1.6 million seed funding round. This fundraising ...
While immune checkpoint inhibitors (anti-PD-1 +/- anti-CTLA-4) are approved as first line treatment for microsatellite instability-high (MSI-H) metastatic colorectal cancer (mCRC), many patients ...
The supplemental biologics license application (sBLA) for Keytruda (pembrolizumab) is still under review by the Food and Drug Administration (FDA) to treat MSI-H cancer. The supplemental biologics ...
Bottom Line: Incorporation of pan-cancer microsatellite instability (MSI) detection into the 74-gene panel Guardant360 liquid biopsy assay showed high concordance with matched tissue samples in nearly ...
Vividion publishes manuscript detailing the discovery and optimization of VVD-214, the company’s covalent inhibitor of WRN.
Dr. Nguyen will discuss the disparities in colorectal cancer outcomes and how precision medicine has the potential to exacerbate health disparities due to differences in access and implementation.
Bottom Line: Incorporation of pan-cancer microsatellite instability (MSI) detection into the 74-gene panel Guardant360 liquid biopsy assay showed high concordance with matched tissue samples in nearly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback